DelveInsight launched a new report on Vitiligo Pipeline Insights, 2020.
“Vitiligo Pipeline Insights Report 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.
The assessment part of the report embraces in-depth Vitiligo commercial assessment and clinical assessment of the Vitiligo pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Vitiligo is a condition in which the skin loses melanin, the pigment that determines the colour of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins.
The Vitiligo therapeutic market in the seven major markets was approximately USD 882.75 million in 2017, which is increasing at a significant Compound Annual Growth Rate (CAGR) during the study period (2017–2028).
The United States accounts for the largest Vitiligo market size, in comparison to the other Seven Major Markets.
Among the EU5 countries, Germany had the highest market size of Vitiligo, with approximately USD 56.27 million in 2017, while France had the smallest Vitiligo market size with approximately USD 22.43 million in 2017.
“The female population was found to be more prevalent than the male population.”
View full report: https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
The key pharma players in Vitiligo market are:
1. Incyte Corporation
2. Clinuvel Pharmaceutical
3. Aclaris Therapeutics
The launch of the emerging therapies is expected to significantly impact the Vitiligo treatment scenario in the upcoming years:-
2. SCENESSE (afamelanotide)
Request for sample pages: https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
Table of Contents:
1. Report Introduction
3. Vitiligo Current Treatment Patterns
4. Vitiligo – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Vitiligo Late Stage Products (Phase-III)
7. Vitiligo Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Vitiligo Discontinued Products
13. Vitiligo Product Profiles
14. Vitiligo Key Companies
15. Vitiligo Key Products
16. Dormant and Discontinued Products
17. Vitiligo Unmet Needs
18. Vitiligo Future Perspectives
19. Vitiligo Analyst Review
21. Report Methodology
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.